The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Grant | Alive

About LaPorte Ag Therapeutics

LaPorte Ag Therapeutics is the developer of MucosImmune, a liquid, topically-administered immunotherapeutic designed to improve on first generation injectable immune therapeutics for cattle.

LaPorte Ag Therapeutics Headquarter Location

Colorado,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • What is LaPorte Ag Therapeutics's latest funding round?

    LaPorte Ag Therapeutics's latest funding round is Grant.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.